1. Home
  2. EVI vs LYEL Comparison

EVI vs LYEL Comparison

Compare EVI & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EVI Industries Inc.

EVI

EVI Industries Inc.

SELL

Current Price

$20.01

Market Cap

204.6M

ML Signal

SELL

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

SELL

Current Price

$13.64

Market Cap

195.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
EVI
LYEL
Founded
1959
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
204.6M
195.8M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
EVI
LYEL
Price
$20.01
$13.64
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $37.63
AVG Volume (30 Days)
92.8K
★ 212.6K
Earning Date
11-09-2026
11-04-2026
Dividend Yield
★ 1.58%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.24
N/A
Revenue
★ $389,830,000.00
$36,000.00
Revenue This Year
$8.40
N/A
Revenue Next Year
$4.71
N/A
P/E Ratio
$87.00
★ N/A
Revenue Growth
★ 10.26
N/A
52 Week Low
$12.75
$7.20
52 Week High
$27.00
$45.00

Technical Indicators

Market Signals
Indicator
EVI
LYEL
Relative Strength Index (RSI) 44.93 54.63
Support Level $19.93 $12.25
Resistance Level $21.37 $14.97
Average True Range (ATR) 1.50 1.67
MACD -0.28 -0.18
Stochastic Oscillator 6.35 43.74

Price Performance

Historical Comparison
EVI
LYEL

About EVI EVI Industries Inc.

EVI Industries Inc is a value-added distributor and service provider in the commercial laundry industry. It sells and leases commercial laundry equipment, specializing in washing, drying, finishing, material handling, water heating, power generation, and water reuse applications. The company supports its equipment offerings with installation, maintenance, and repair services through a large network of trained technicians. It serves a wide range of customers, including commercial, industrial, institutional, government, and retail sectors. Geographically, the company serves various countries including United States, Canada, the Caribbean, and Latin America.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: